Navarro Ledesma Santiago, Hamed-Hamed Dina, González-Muñoz Ana, Pruimboom Leo
Department of Physiotherapy, Faculty of Health Sciences, Campus of Melilla, University of Granada, Querol Street 5, 52004 Melilla, Spain.
Department of Physiotherapy, University Chair in Clinical Psychoneuroimmunology, University of Granada and PNI Europe, 52004 Melilla, Spain.
Cancers (Basel). 2023 Aug 28;15(17):4297. doi: 10.3390/cancers15174297.
Cancer is the leading cause of death worldwide, with the most frequent being breast cancer in women, prostate cancer in men and colon cancer in both sexes. The use of metabolomics to find new biomarkers can provide knowledge about possible interventions based on the presence of oncometabolites in different cancer types.
The primary purpose of this review is to analyze the characteristic metabolome of three of the most frequent cancer types. We further want to identify the existence and success rate of metabolomics-based intervention in patients suffering from those cancer types. Our conclusions are based on the analysis of the methodological quality of the studies.
We searched for studies that investigated the metabolomic characteristics in patients suffering from breast cancer, prostate cancer or colon cancer in clinical trials. The data were analyzed, as well as the effects of specific interventions based on identified metabolomics and one or more oncometabolites. The used databases were PubMed, Virtual Health Library, Web of Science, EBSCO and Cochrane Library. Only nine studies met the selection criteria. Study bias was analyzed using the Cochrane risk of bias tool. This systematic review protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023401474).
Only nine studies about clinical trials were included in this review and show a moderate quality of evidence. Metabolomics-based interventions related with disease outcome were conflictive with no or small changes in the metabolic characteristics of the different cancer types.
This systematic review shows some interesting results related with metabolomics-based interventions and their effects on changes in certain cancer oncometabolites. The small number of studies we identified which fulfilled our inclusion criteria in this systematic review does not allow us to draw definitive conclusions. Nevertheless, some results can be considered as promising although further research is needed. That research must focus not only on the presence of possible oncometabolites but also on possible metabolomics-based interventions and their influence on the outcome in patients suffering from breast cancer, prostate cancer or colon cancer.
癌症是全球主要死因，女性中最常见的是乳腺癌，男性中是前列腺癌，男女两性中均为结肠癌。利用代谢组学寻找新的生物标志物可以提供基于不同癌症类型中肿瘤代谢物存在情况的可能干预措施的相关知识。
本综述的主要目的是分析三种最常见癌症类型的特征代谢组。我们还想确定基于代谢组学的干预措施在患有这些癌症类型的患者中的存在情况和成功率。我们的结论基于对研究方法质量的分析。
我们在临床试验中搜索了研究乳腺癌、前列腺癌或结肠癌患者代谢组学特征的研究。分析了数据以及基于已确定的代谢组学和一种或多种肿瘤代谢物的特定干预措施的效果。使用的数据库有PubMed、虚拟健康图书馆、科学网、EBSCO和考克兰图书馆。只有九项研究符合入选标准。使用考克兰偏倚风险工具分析研究偏倚。该系统评价方案已在国际前瞻性系统评价注册库（PROSPERO：CRD42023401474）注册。
本综述仅纳入了九项关于临床试验的研究，证据质量中等。基于代谢组学的干预措施与疾病结局相关，但不同癌症类型的代谢特征没有变化或变化很小，存在矛盾。
本系统评价显示了一些与基于代谢组学的干预措施及其对某些癌症肿瘤代谢物变化的影响相关的有趣结果。我们在本系统评价中确定的符合纳入标准的研究数量较少，无法得出明确结论。然而，一些结果可以被认为是有前景的，尽管还需要进一步研究。该研究不仅必须关注可能的肿瘤代谢物的存在，还必须关注基于代谢组学的可能干预措施及其对乳腺癌、前列腺癌或结肠癌患者结局的影响。
